Loading
A phase 1/2 trial of JAB-23E73 in advanced solid tumours, run by Jacobio Pharmaceuticals Co., Ltd., now recruiting.
JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration is a phase 1/2 interventional study registered as NCT06973564 by Jacobio Pharmaceuticals Co., Ltd., with 294 participants planned, started 2025-05-29 and due to reach its primary completion in 2027-11. Interventions recorded: JAB-23E73.
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jacobio Pharmaceuticals, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Jacobio Pharmaceuticals and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.